Division of Pediatric Anesthesiology, Children's Hospital Colorado, Aurora, CO, USA.
Department of Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA.
J Matern Fetal Neonatal Med. 2023 Dec;36(1):2130241. doi: 10.1080/14767058.2022.2130241. Epub 2022 Oct 3.
Achieving functional recovery after cesarean delivery is critical to a parturient's ability to care for herself and her newborn. Adequate pain control is vital, and without it, many other aspects of the recovery process may be delayed. Reducing opioid consumption without compromising analgesia is of paramount importance, and enhanced recovery pathways have generated considerable interest given their ability to facilitate this. Our group's process for reducing opioid consumption for cesarean delivery patients evolved over time. We first demonstrated that providing additional incisional pain control with continuous bupivacaine infusions through wound catheters, with the concurrent use of neuraxial morphine, reduced postoperative opioid use. Iterations of an enhanced recovery after cesarean (ERAC) delivery pathway were then implemented after the consensus statement for ERAC was issued to eliminate variability in both hospital course and in the treatment of postoperative pain. In this retrospective cohort analysis, we sought to identify whether adding ERAC protocols to our existing combination of neuraxial morphine and wound soaker catheters further reduced opioid consumption after cesarean delivery.
A retrospective cohort analysis of cesarean deliveries from 2015 through 2020 was performed. Deliveries were divided by analgesic pathway into four time-periods - neuraxial morphine in addition to as needed opioid and non-opioid analgesics; continuous wound catheter infusions of local anesthetic, neuraxial morphine in addition to as needed opioid and non-opioid analgesics; : continuous wound catheter infusion of local anesthetic, neuraxial morphine, in addition to scheduled non-opioid analgesics (acetaminophen and ibuprofen) every 6 h, alternating in relation to one another so that one is given every 3 h; continuous wound catheter infusion of local anesthetic, neuraxial morphine in addition to non-opioid analgesics scheduled together every 6 h (to facilitate periods of uninterrupted rest). Cumulative and average daily opioid use for postoperative days (POD) 1-4 were analyzed using ANOVA and a mixed effect model, respectively.
Average daily opioid consumption and total cumulative opioid consumption POD 1-4 (morphine milligram equivalents) for both early and late ERAC groups (23.9 ± 31.1 and 29.4 ± 35.1) were significantly reduced compared to control and wound soaker groups (185.1 ± 93.7 and 134.8 ± 77.1) ( < .001).
The addition of ERAC protocols to our standardized multimodal analgesic regimen (local anesthetic wound infusion catheters and neuraxial morphine) for cesarean delivery significantly reduced postoperative opioid consumption.
剖宫产术后实现功能恢复对产妇照顾自己和新生儿的能力至关重要。充分的疼痛控制至关重要,如果没有疼痛控制,恢复过程的许多其他方面可能会延迟。减少阿片类药物的使用而不影响镇痛效果至关重要,鉴于其能够促进这一点,增强型康复途径引起了极大的兴趣。我们小组为剖宫产患者减少阿片类药物使用的方法随着时间的推移而不断发展。我们首先证明,通过伤口导管持续输注布比卡因,同时使用鞘内吗啡,为切口提供额外的疼痛控制,可以减少术后阿片类药物的使用。在发布增强型剖宫产康复(ERAC)共识声明后,实施了 ERAC 分娩途径的迭代,以消除医院流程和术后疼痛治疗中的变异性。在这项回顾性队列分析中,我们试图确定在现有的鞘内吗啡和伤口浸泡导管组合的基础上添加 ERAC 方案是否会进一步减少剖宫产术后的阿片类药物消耗。
对 2015 年至 2020 年的剖宫产分娩进行回顾性队列分析。根据镇痛途径将分娩分为四个时间段:鞘内吗啡加按需阿片类药物和非阿片类药物镇痛;连续伤口导管输注局部麻醉剂,鞘内吗啡加按需阿片类药物和非阿片类药物镇痛;连续伤口导管输注局部麻醉剂,鞘内吗啡,加每 6 小时给予一次计划的非阿片类药物(对乙酰氨基酚和布洛芬),彼此交替,每 3 小时给予一次;连续伤口导管输注局部麻醉剂,鞘内吗啡加每 6 小时给予一次计划的非阿片类药物镇痛(以促进不间断休息期)。使用方差分析和混合效应模型分别分析术后第 1-4 天的累积和平均每日阿片类药物使用量。
早期和晚期 ERAC 组(23.9±31.1 和 29.4±35.1)的术后第 1-4 天平均每日阿片类药物使用量和总累积阿片类药物消耗量(吗啡毫克当量)明显低于对照组和伤口浸泡组(185.1±93.7 和 134.8±77.1)( < .001)。
在我们的剖宫产标准化多模式镇痛方案(局部麻醉伤口输注导管和鞘内吗啡)中添加 ERAC 方案可显著减少术后阿片类药物的消耗。